Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (10069)	10/23/1997 7:19:00 PM
From: DrJerry	Respond to of 32384

Stephen: Re: analyst coverage- I too am concerned- on the day the deal was announced, Ligand was not listed in the company index of the NYTimes business section despite being mentioned in a Lilly blurb- while one can blame editorial oversite it is certainly incumbent on management to continue the push for analyst and public awareness- one can only presume that had an announcement been made when LGND was making intraday highs, that we would be looking at establishing a base of 18 instead of 16. So lets keep up the posts at even a greater clip!!!!

To: Hippieslayer who wrote (10069)	10/23/1997 10:08:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

>>I am still baffled as to how the LGND/LLY deal was received by Wall St.The analysts that cover the stock, based on what was posted on this thread, all seemed to think is was better than what they originally expected-one terming it a "blockbuster". I would have thought, based on the magnitude of the deal, that other brokerage firms who are not covering the stock would do so. I wasn't expecting the whole street to go gaga over LGND, but the stock is no better off now than it was before the deal<< There are a few analysts we haven't heard from yet. Maybe they are still trying to figure it out. There may be more coverage--it takes time for these things to occur. I think we all expected that the deal would push the stock a lot higher. Of course there have been some bad hair days for the market lately, but LGND wasn't surging ahead even before that. The company is certainly better off than it was before the deal. The stock should follow. Thing about COR and IDPH is that they have drugs with larger markets already approved or closer to approval. LGND is a ways from approval of a drug with a big indication. Still, seems like prices should trend higher over the next few months. LLY gave LGND a very strong seal of approval.

To: Hippieslayer who wrote (10069)	10/24/1997 9:42:00 AM
From: lavalamp	Respond to of 32384

Stephen, Regarding the lack of new brokerage coverage, many times the brokerage firm and the analyst have positions in the stock they recommend. Thus, they might be accumulating the stock on this weakness and when fully positioned will release the recommendation (after also telling a few select clients before the general masses find out). Of course, I am looking at this with my Rose colored glasses on. BTW: they are designed just for looking at computer screens and LGND;)